Microchip platforms for multiplex single-cell functional proteomics with applications to immunology and cancer research
© BioMed Central Ltd 2013
Published: 29 August 2013
Skip to main content
© BioMed Central Ltd 2013
Published: 29 August 2013
Single-cell functional proteomics assays can connect genomic information to biological function through quantitative and multiplex protein measurements. Tools for single-cell proteomics have developed rapidly over the past 5 years and are providing approaches for directly elucidating phosphoprotein signaling networks in cancer cells or for capturing high-resolution snapshots of immune system function in patients with various disease conditions. We discuss advances in single-cell proteomics platforms, with an emphasis on microchip methods. These methods can provide a direct correlation of morphological, functional and molecular signatures at the single-cell level. We also provide examples of how those platforms are being applied to both fundamental biology and clinical studies, focusing on immune-system monitoring and phosphoprotein signaling networks in cancer.
Non-genetic cellular heterogeneity is a universal feature of any cell population [1, 2]. Although this heterogeneity is often ascribed to some process (such as stochastic gene expression), it is also intrinsic to the finite nature of a single cell . This heterogeneity is not without consequences; for example, it can contribute to the diversity of an immune response or to the emergence of therapeutic resistance in cancers. However, the detailed role of cellular heterogeneity in such processes is not always easy to capture. If some parameter is measured on a statistical number of 'identical' single cells, that parameter can almost always be used to stratify those cells into multiple populations. Whether the variance in the assayed parameter is biologically relevant may be debatable. Parameters for which the variance is thought to have high biological relevance are the levels of functional proteins. These include the signaling proteins (such as cytokines) that are secreted by immune cells, or the phosphorylated kinases and related effector proteins that comprise the heart of growth factor signaling networks within cells.
A single-cell functional proteomics assay is one that measures the quantity and functional state (such as phosphorylation) of a given protein or panel of proteins across many otherwise identical cells. A measurement of the average level of a protein requires many single-cell measurements. Such measurements, if compiled as a histogram of the frequency of observation versus the measured levels, reflect the fluctuations of that protein. Functional protein fluctuations can reflect changes in cellular activity, such as immune-cell activation or the activation or inhibition of protein signaling networks within, for example, tumor cells. However, the usefulness of fluctuations significantly expands with absolute quantification and increased numbers of proteins assayed per cell (multiplexing).
When multiple proteins are assayed from single cells, protein-protein correlations and anti-correlations are directly recorded. For cell-surface markers, such measurements provide a way to enumerate and sort highly defined cellular phenotypes. A multiplex analysis of secreted effector proteins from immune-cell phenotypes can provide a powerful view of immune-system function. For intracellular signaling networks, such as those associated with growth factor signaling, correlations and anti-correlations between phosphoproteins can indicate activating and inhibitory interactions, respectively. With increased multiplexing, such measurements increasingly resolve the structure of signaling networks. If the measurements are truly quantitative, it becomes possible to assess how perturbations to cells influence changes in the chemical potential of the measured proteins. This, in turn, allows the introduction of predictive models derived from physicochemical principles.
Single-cell functional proteomics can connect genomic information with biological context and biological function. For example, certain classes of genetically engineered immune cells are increasingly used for certain anti-cancer therapies. This clonal population of cells can show great functional heterogeneity [4, 5]. That heterogeneity, which can be characterized by single-cell proteomics, arises from many epigenetic factors (biological context), such as exposure to specific cell types or to signaling proteins. This and other examples are discussed in detail below.
Here, we describe emerging technologies and their associated applications that are designed to characterize cellular heterogeneity by single-cell functional proteomics. We first provide an overview of the rapid development of single-cell proteomics tools that has occurred over the past half decade. We then discuss specific biological or clinical challenges that are either uniquely or most easily addressed by single-cell functional proteomics. These challenges include basic biology studies, such as the kinetics of T-cell activation, or the identification of effector proteins associated with cellular motility. Clinical applications include advanced immune monitoring of patients with a variety of disease conditions, ranging from HIV to cancer. Cancer biology applications include experiments aimed at resolving how targeted therapeutics alter the phosphoprotein signaling networks that are hyperactivated in many tumors. Each problem provides a venue for discussing platform advantages and limitations. We focus on multiplex microfluidics/nanotechnology-based platforms as these tools are proving uniquely suited for quantitative, single-cell functional proteomics.
Single-cell functional proteomics tools
Numbers and types of poteins assayed
Statistical accuracy and signal quantification
Notes and features
Flow cytometry methods
Fluorescence flow cytometry
Around 15 proteins (mostly membrane proteins, a few cytoplasmic proteins)
104 cells s-1
500 copies per cell
90% phenotyping accuracy; relative protein abundance
Standard for sorting and enumeration of cellular phenotypes. Secretion blocked and cells fixed for cytoplasmic proteins
Mass flow cytometry
Around 35 membrane and intracellular proteins, likely expandable
103 cells s-1
>103 copies per cell
Good cell counting statistics; relative protein abundance
Cells handled in bulk prior to analysis. Secretion blocked and cells fixed for cytoplasmic proteins
1-3 secreted proteins
6 spots per 105 cells
Quantitative for percentage active cells
Cells secrete proteins onto antibody coated surfaces; secretion activity correlated with cell location
3-4 membrane or intracellular proteins and cell size
103-104 cells per chip
105 fluoro-phores per μm2
Good cell counting statistics; relative protein abundance
Cells are fixed and stained (in bulk) with fluorescent antibodies; protein assay and cell location spatially correlated
1 intracellular protein
<103 cells per chip
Good cell counting statistics; relative protein abundance
Single cells separated and imaged on chip; continuous monitoring of cell physiology
1 membrane or intracellular protein
102 μdrops s-1
Good cell sampling statistics
Cells entrained in microdroplets; microdroplet composition control permits screening cells
3 secreted or 3 membrane proteins
104-105 cells per chip
Very good cell number statistics; relative protein abundance
Cells isolated in miocrowells; surface immunoassays; proteins colorimetrically detected; secretome kinetics from single cells; proteomeic and functional assays from same cell
Single cell barcode chips
About 20 secreted, membrane, or cytoplasmic proteins, expandable
103-105 cells per chip
Good cell counting statistics, absolute quantification, 10% measurement error per protein per cell
Cells isolated in microchambers, miniature antibody arrays yield spatial separation of specific protein assays; proteomeic and functional assays from same cell; single cells or defined small cell populations accessed.
Surface methods (Table 1) for single cell functional proteomics include the established and relatively simple and inexpensive ELISpot technique for detecting protein secretion from live cells . Cells are immobilized on an antibody-coated surface, and sandwich-type immunoassays are utilized to detect secreted proteins in the vicinity of individual cells.
Microfluidics technologies constitute the third class of tools. Common advantages of microfluidics tools are that they can often be cheaply manufactured in large quantities, they can handle very small numbers of cells and require only tiny quantities of expensive reagents, and they may often be customized to allow for on chip incubation, cell lysis, and so on. For single cell proteomics, microfluidics platforms fall into two groups - those in which the cells are stained to identify specific proteins, and those for which proteins are released from the cells and measured using surface immunoassays. The first group includes the image cytometry, cell-array, and micro-droplet techniques. Early variations of such tools detected proteins from single cells by imaging stained cells, or by flowing the labeled cells or cell-encapsulation droplets through a microfluidic channel designed to allow fluorescence detection. These were basically microchip versions of FFC or FACS . More recent approaches have significantly diverged to take advantage of some of the unique aspects of microfluidics. For example, cells can be spatially segregated into large arrays (cell arrays [11–15]), or they can be entrained within arrays of drops [16–18]. Such manipulations are followed by immunostaining of membrane proteins, followed by automated imaging to quantify single-cell fluorescence signals. These approaches can offer control over the cell environment before analysis, which make them attractive screening tools. One disadvantage of these and other cell-staining approaches [19, 20] is that they have limited multiplexing capacity.
The most advanced microfluidic single-cell proteomics tools use surface-immobilized antibodies for separating protein detection from cell manipulation (Figure 1c,d). This approach has several advantages: it can yield increased multiplexing capacity, it can be extended to assays for secreted, cytoplasmic, and membrane proteins, and measurements of cellular functions can be integrated with the proteomics assays. The experimental challenge is that a given cell may only produce between a few hundred and a few thousand copies of a protein of interest - such numbers are typical for many phosphoproteins or secreted signaling proteins. The solution is to enclose the cell within a microenvironment with a volume of about 1 nl. In this way, the resultant protein concentration can be sufficiently high to allow detection with standard immunoassays. The beauty of microfabrication is that such tiny volume assays can be repeated many times, in parallel, on a single microchip. The microengraving approach developed by Love's group (Figure 1c) [21–23] uses small volume microwells in an array format to isolate and culture single cells. A 'microengraved' (antibody-coated) substrate is used to cap the microwell array and to capture secreted proteins. Proteins are detected using sandwich-type ELISA immunoassays. Different fluorophores colorimetrically distinguish between different detection antibodies to allow the simultaneous detection of about three secreted proteins. The microengraved substrate can be replaced multiple times in situ, thus enabling kinetic studies (Figure 1c(ii,iii)) at the single-cell level. The multiplexing capacity of the microengraving method can be increased using fluorophore-labeled antibody staining of membrane proteins; fluorescence imaging of the captured cells yields information on membrane protein levels (to identify cellular phenotypes), and the microengraved substrate assays for secreted proteins (to assess cellular function).
A related approach is the single-cell barcode chips (SCBCs). The basic concept is to pattern a many-element capture antibody array in each single-cell microwell so that different proteins are detected at different designated array spots. The key enabling technology of SCBCs is the miniature antibody arrays. A related challenge is that antibody arrays are not stable to the physical conditions of microfluidics device fabrication. The solution has been to couple the technique of DNA-encoded antibody libraries (DEAL)  with microfluidics-based flow patterning. Specifically, an elastomer film is molded so that it contains a series of long, serpentine channels. It is adhered to the top of a glass slide. Solutions containing a different single-stranded DNA (ssDNA) oligomer are flowed through each channel. Those solutions evaporate. The molded elastomer is then removed, leaving a series of 10 to 20 µm wide stripes of different ssDNA oligomers across the glass substrate. A second elastomer layer, patterned with between 300 and 10,000 microchambers for single-cell assays, is adhered to the glass slide. The design is such that each microchamber contains a full complement of ssDNA stripes. Just before use, these miniature ssDNA arrays are converted into antibody arrays using a cocktail of complementary ssDNA-labeled antibodies. The resultant antibody array (the barcode)  provides the detection technology for SCBCs (Figure 1d(ii)) [4, 26]. Up to 20 functional proteins have been assayed per cell , and the limit is probably around 100. Specific SCBC designs enable cell lysis, thus allowing cytoplasmic, membrane, and secreted proteins to be assayed from the same single cell. SCBC assays can yield absolute protein level quantification  and access to discrete cell populations (one cell, two cells, three cells and so on)  (Figure 1d(iii)). Both the SCBC and microengraving platforms can be integrated with multicolor FACS to enable the integration of phenotype analysis with functional proteomics . Quantitative data comparison across different SCBC assays  allows clinical studies or investigations in which statistical cell behaviors are compared across a perturbation series.
Most microfluidics tools enable the single cells to be imaged. When integrated with proteomics measurements, this can enable several interesting assays, such as correlating cell motility or cell-cell interactions [28, 30] with specific protein levels. Unlike flow cytometry analyses, cells can remain in their native morphology so that cell size, spreading, or motility can be correlated with proteomic signature for each cell assayed . The ability of a cytotoxic T cell to kill the target cell can be directly visualized under an optical microscope. Once conducted in a microengraving device, this allows direct comparison of cytolic activity with the protein profile of the same T cell . Finally, cells can be recovered from these types of assays for additional analysis, or for establishing clonal cell lines with desired properties . This direct coupling of many different assays on the same single cells is, so far, a unique attribute of these microfluidics platforms.
Immune cells are classified along the hematopoietic lineage, starting with myeloid and lymphoid lineages. A triumph of immune system biology has been the identification of cell surface markers that allow, by FACS, the enumeration and sorting of specific immune-cell phenotypes from blood or tissues. For example, a cytotoxic T cell is defined by the cell surface markers Cluster of Differentiation (CD)3, CD45, and CD8, with additional markers specifying the antigen specificity of the T cell receptor (TCR) or providing further phenotypic classification, such as effector memory. However, functional information requires assays of secreted effector proteins (such as cytokines and cytotoxic granules) that mediate the tasks of target killing, self-renewal, recruitment of other immune cell types, and inflammation. Because of the variety of potential pathogen targets, cellular immunity is functionally heterogeneous. Recent studies using different single-cell proteomics platforms have begun to capture and characterize this heterogeneity.
The function of an immune cell is largely delineated by a range of proteins it produces. Early efforts to profile multiple immune effector functions of single immune cell function used ICS FFC. Betts et al.  measured five functions (degranulation and levels of interferon (IFN)-γ, macrophage inflammatory protein (MIP)-1b, tumor necrosis factor (TNF)-α, and interleukin (IL)-2) from single HIV-specific CD8+ T cells collected from chronically HIV-infected individuals and people whose HIV infection has not progressed over a long term (called non-progressors or elite controllers). The number of effector functions displayed in T cells from people with chronic HIV was limited relative to those from non-progressors, and the number of functions ('polyfunctionality') was inversely correlated with viral load. Another example of the use of ICS FFC was by Darrah et al. , who showed that the degree of protection against Leishmania major infection in mice is predicted by the frequency of CD4+ T cells simultaneously producing IFN-γ, IL-2, and TNF-α. More recent studies have used ICS mass cytometry. For example, Newell and coworkers  used this approach to assay 17 membrane protein markers, 6 intracellular cytokines and 2 cytotoxic granules from stimulated CD8+ T cells from healthy patients. They found that the cytokine secretion profiles were almost statistically distributed across the individual cells, but there were distinct niches occupied by virus-specific cells.
Love and colleagues used microengraving to carry out two sets of studies that coupled functional behaviors with functional proteomics on single T cells [31, 37]. In the first , they measured cytolytic activity of CD8+ T cells by performing live-cell imaging of these cells cultured together with single target cells in a microengraving device. This allowed the killing ability of individual T cells to be directly correlated with the production of multiple cytokines, and it revealed a discordance between cytokine secretion and cytolysis. The authors  found that the majority of in vivo primed, circulating HIV-specific CD8+ T cells were discordant for cytolysis and secretion of cytokines, notably IFN-γ, when encountering cognate antigen presented on defined numbers of cells. In their second study , they investigated the kinetics of cytokine production using serial analyses of single primary human T cells under various conditions (Figure 1c). They showed that for multifunctional T helper 1-skewed cytokine responses (IFN-γ, IL-2, and TNF-α), cells predominantly release those cytokines sequentially, rather than simultaneously. These kinetic trajectories were associated with states of cell differentiation, suggesting that transient programmatic activities of many individual T cells contribute to sustained, population-level responses.
The value of absolute quantification was demonstrated by Shin et al. , who used a 12-plex SCBC assay to investigate how the secretome of lipopolysaccharide-stimulated macrophage cells responded to neutralizing antibody perturbations. They reported on the use of statistical-physics-derived models as a means for correctly predicting how specific secreted protein levels would vary with the perturbations. We cover related concepts below in our discussions of phosphoprotein signaling networks.
For many cancers, genomic surveys are revealing a rich molecular landscape of altered signal transduction cascades that often cluster along a set of druggable core pathways. In fact, these pathways contain many of the targets of the newer generations of targeted cancer therapies . However, the translation of genomic data into effective clinical treatments has not been straightforward. This is at least partly because non-genetic cell-to-cell variability is profound in drug responses and resistance development, yet it cannot be readily captured from genome sequencing data. A recent editorial  has pointed out that capturing the functional protein signaling networks may prove valuable for this purpose, because it is those 'signaling proteins, not the genes per se, that are responsible for the phenotypes of tumors and for the emergence of therapeutic resistance'. Single-cell proteomics provides the most direct approach for elucidating signaling network structure and coordination, and for interrogating how that coordination is disrupted by drugs. It thus may provide a powerful tool for translating genomic information into effective clinical practices for many highly challenging types of cancer .
An early single-cell study of phosphoprotein signaling  used ICS FFC to assay, in various cancer cells, the cytokine responses of six phosphoproteins, mostly from the signal transducers and activators of transcription (STAT) family. Signaling network heterogeneity and network remodeling was observed in both normal cells in a hematopoietic compartment  and cancerous cells such as acute myeloid leukemia , suggesting that cells could be classified according to functional phenotype. There have been other highly multiplex studies of phosphoprotein signaling networks using flow (or mass) cytometry  or image cytometry  over the past decade, and more recent work using SCBC platforms [27, 28, 45]. Such a sparse literature (especially compared with the routine use of cytometry techniques for cellular phenotyping) highlights the difficulty of these assays, even though the specific studies have illustrated their value. We now turn to discussion of this value, within the specific context of cancer pathways.
Population heterogeneity can arise from factors such as the stochastic nature of intracellular events controlled by low-copy-number transcription factors  or through cell-cell interactions [48, 49]. The net result is often high-amplitude fluctuations at the single-cell level but stable distributions across a population . The concept of a stable population existing in the presence of random fluctuations is reminiscent of many physical systems that are successfully understood using statistical physics. Thus, tools derived from that field can probably be applied to using fluctuations to determine the nature of signaling networks. This approach contrasts with traditional biology thinking, which might seek to classify the population into functional phenotypes.
Wei and coworkers  reported simulations to account for how an increasing signaling activity of a hypothetical protein would be reflected in the fluctuations of the activated state of that protein (Figure 4a). They used a mean field theory, which treated the increasing signaling activity of the hypothetical protein as arising from the statistically averaged (mean field) influences of effector proteins. As the activity increases, the fluctuations shift to higher average copy numbers and are increasingly dispersed. The simulations captured how the experimentally measured fluctuations of hypoxia inducible factor (HIF)-1α in single glioblastoma multiforme (GBM) cancer cells evolve as the cells were exposed to increasingly hypoxic conditions. HIF-1α is, in fact, steadily activated as the cells transition from normoxia to hypoxia . This conclusion can be drawn by simply inspecting the HIF-1α fluctuations.
Quantitative, multiplexed assays can also provide protein-protein correlations. This means that one can use statistical models that explicitly account for protein-protein interactions (Figure 4b,c) and begin defining the state of the signaling network. Shin et al.  developed a quantitative Le Chatelier principle that relates how the changes in average signaling protein levels following a weak perturbation to a cell correlate to the changes in the chemical potentials of those proteins. The Le Chatelier principle states that a stable system will respond to a weak perturbation so as to restore that stability. The theory is summarized by the matrix equation . Here, is a column vector with P components representing the average protein levels of the P assayed proteins; β is 1/k B T, where k B is Boltzmann's constant and T is temperature; Σ is a P × P matrix where each element is the experimentally measured covariance of a specific protein Pi with another specific protein Pj; and Δµ is a column vector whose P components describe the change in the chemical potentials of the P proteins, due to a change in external conditions (the perturbation). If the predicted changes in protein levels match experiment, the implication is that the signaling network is described by a stable state and responds to a weak perturbation so as to restore that state. If the calculation does not match experiment, then either the perturbation is strong or the signaling network is not stable. The theoretical tools were coupled with single-cell proteomics assays of mammalian target of rapamycin (mTOR) complex1 (C1) and HIF-1α signaling in model GBM cancer cells, to capture the response of these networks to the transition from normoxia (21% O2 partial pressure (pO2)) to hypoxia (1% pO2) (Figure 4d). mTORC1 signaling was identified as one stable state above 2% pO2 and as a different stable state between 1.5% and 1% pO2, with a switch between those two states near 2 to 1.5% pO2. Within this narrow window of pO2, the models predicted that mTORC1 would be unresponsive to inhibitors, but that it could be drugged at higher or lower pO2. These surprising predictions were found to be correct in both cell lines and tumor models .
These results have several implications. First, single-cell proteomics, coupled with approaches derived from statistical physics, can yield detailed (and often surprising) predictions, which can be experimentally validated. Traditional biology experiments on bulk cell cultures or disease models rarely yield such detailed predictions. Furthermore, cellular heterogeneity was not assessed to capture functional phenotypes. Instead the fluctuations were analyzed to identify a stable state or to point to where that state was unstable. Although this general concept is not new, the experimental challenge has been to find approaches that can accurately sample the relevant fluctuations. Related examples have drawn from model systems using, for example, green fluorescent protein reporter genes to provide signatures of protein fluctuations. In one such case , time-lapse live-cell microscopy was used to capture specific promoter activity fluctuations in fibroblast cells. The authors  identified switching rates between two stable states within the cells. A major advantage of the multiplexed platforms, such as SCBCs, is that fluctuations of broadly sampled signaling networks from primary cells can be measured, allowing predictive applications to non-model systems, with extensions to clinically relevant problems.
Extending such assays to discrete cell populations (unique to microfluidic/nanotechnology platforms) allows the investigation of cell-cell interactions. A few studies have explored the inhibitory or activating nature of such interactions using a combination of protein assays and/or functional observations [52–55]. A recent study  correlated the levels of a panel of phospho- (and effector) signaling proteins in model GBM cells, with cell-cell distances in two-cell assays. This indicated that a detailed knowledge of pairwise cell interaction functions could be used to predict specific properties of larger cell populations. Such experiments again draw from concepts derived from statistical physics , and may eventually allow complex phenomena within tissue microenvironments to be understood.
The advance of methods for single-cell functional proteomics has been rapid, and the majority of tools discussed here did not exist 5 years ago. These platforms offer unique and emerging opportunities. The coupling of functional and proteomic assays at the single-cell level is one such advantage. Most microfluidic proteomics platforms, however, cannot yet match the statistics and throughput of cytometry tools. However, as these technologies evolve, the range of potential applications will continue to expand, as will the thinking regarding how the resultant datasets can be interpreted. It is likely that, in the near future, microchip platforms will enable as many as 100 proteins to be assayed from single cells, and platforms that enable 10- to 20-plex assays will become routine biological and clinical tools. However, beyond about 100 proteins, all (microchip or cytometry) single-cell proteomics approaches will ultimately be limited by antibodies or other capture agents. Thus, an important underlying challenge is the production of high-performance and robust protein capture agents at low cost. A second outstanding challenge is the development of a capture-agent-independent approach that allows discovery.
One area that has not been covered here is that of mass spectrometry. However, that field has seen remarkable advances over the past few years, and single-cell proteomics may be on the horizon. Targeted proteomics using mass spectrometry has evolved to the extent that small cell numbers, or even single cells, can be analyzed for highly abundant proteins. Protein processing with immobilized enzymes  or novel column chromatography methods  may eventually allow mass spectrometry to be a single-cell proteomics discovery tool. Finally, the idea that single-cell functional proteomics can provide a conduit to the predictive world of statistical physics is exciting, but the benefits (and limitations) of this type of thinking are largely untapped. It is certain, however, that as measurement quantification, multiplexing capacity, statistical sampling, and sensitivity all improve, so will the power of the models that can use these data to resolve what are otherwise complex biological problems.
Some of the work reviewed here was supported by the National Cancer Institute (5U54 CA119347 and R01 CA170689-01 to JRH) and the National Institutes of Health (NIH 1 U01 CA164252-01 to RF and U54 CA143798 to RF).